NASDAQ:KIN - Kindred Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.00 +0.35 (+3.29 %)
(As of 06/24/2018 06:57 AM ET)
Previous Close$11.00
Today's Range$10.15 - $11.15
52-Week Range$6.55 - $12.00
Volume942,475 shs
Average Volume233,205 shs
Market Capitalization$300.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
Kindred Biosciences logoKindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Debt-to-Equity RatioN/A
Current Ratio18.56
Quick Ratio18.56

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book3.67

Profitability

EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-41.64%
Return on Assets-39.66%

Miscellaneous

Employees63
Outstanding Shares28,200,000

The Truth About Cryptocurrencies

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, hitting analysts' consensus estimates of ($0.36). View Kindred Biosciences' Earnings History.

What price target have analysts set for KIN?

6 Wall Street analysts have issued twelve-month price targets for Kindred Biosciences' stock. Their predictions range from $11.00 to $16.75. On average, they anticipate Kindred Biosciences' share price to reach $13.25 in the next twelve months. View Analyst Ratings for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 51)
  • Ms. Denise M. Bevers, Co-Founder, Chief Operating Officer and Sec. (Age 51)
  • Ms. Wendy K. Wee, CFO & Principal Accounting Officer (Age 65)
  • Dr. Hangjun Zhan, Chief Scientific Officer
  • Dr. Noe Reyes D.V.M, Medical Director

Has Kindred Biosciences been receiving favorable news coverage?

News headlines about KIN stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kindred Biosciences earned a news sentiment score of 0.10 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.90 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.84%), BlackRock Inc. (3.91%), General American Investors Co. Inc. (2.12%), Wells Fargo & Company MN (1.28%), New York State Common Retirement Fund (0.86%) and B. Riley Financial Inc. (0.46%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which major investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Amtrust Financial Services Inc., General American Investors Co. Inc., BlackRock Inc. and Wells Fargo & Company MN. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Which major investors are buying Kindred Biosciences stock?

KIN stock was purchased by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Citigroup Inc., New York State Common Retirement Fund and Dimensional Fund Advisors LP. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $11.00.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $300.36 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (KIN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  381
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.